Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21063738 | 1.00 | CHRNA7 (0.41) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL4280104 | 1.00 | CHRNA7 (0.41) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL23406281 | 0.98 | SLC6A12 (0.42) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL2422058 | 0.98 | SLC6A12 (0.42) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL29271818 | 0.98 | CHRNA7 (0.40) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL26105242 | 0.98 | SLC6A12 (0.42) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL21095889 | 0.90 | SLC6A12 (0.39) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL21095754 | 0.90 | SLC6A12 (0.39) | CHRNA7CHRM2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL660508 | 0.82 | CHRNA7 (0.45) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL6650217 | 0.82 | CHRNA7 (0.40) | CHRNA7CHRM2CYP2D6CHRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260147006-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12298319-B2 | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| EP-3724188-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | CHRNA7 2271/4885CHRM2 4042/4885SLC6A12 3989/4885 |
| US-12298319-B2 | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM4 | CHRNA7 15/4885CHRM2 2/4885SLC6A12 1470/4885 |
| US-20260147006-A1 | SCREENING METHOD | CHRM1, CHRM4, CHRM5 | CHRNA7 15/4885CHRM2 4/4885SLC6A12 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.